Get the Stockscreener App
407.27
3.38%
-14.24
Pre-market:
411.00
3.73
+0.92%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $407.27, with a volume of 2.49M.
It is down -3.38% in the last 24 hours and down -7.04% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$421.51
Open:
$421.72
24h Volume:
2.49M
Relative Volume:
0.96
Market Cap:
$220.18B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
28.32
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+0.30%
1M Performance:
-7.04%
6M Performance:
+15.28%
1Y Performance:
+36.44%
1-Day Range:
$407.13
$422.80
1-Week Range:
$404.19
$426.59
52-Week Range:
$288.00
$447.03
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
407.27 | 224.15B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,149.85 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
258.66 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.93 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
143.81 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.05 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know - TradingKey
More Than Skin Deep: Understanding Discoid Lupus Erythematosus - Amgen
Amgen (NASDAQ:AMGN) Scores Late-Stage Immunology Win - kalkinemedia.com
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Amgen reports Phase 3 results and Amgen stock trades at EUR 371.13 - AD HOC NEWS
Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update? - Simply Wall Street
Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial - insights.citeline.com
Homozygous Familial Hypercholesterolemia (HoFH)7MM Market, Epidemiology, and Forecast - GlobeNewswire Inc.
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody - Fierce Biotech
Amgen Inc (AMGN) Shares Surge 1.3% -- What GF Score of 87 Tells Investors - GuruFocus
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen (NASDAQ:AMGN) Stock: Dazodalibep's Phase 3 Win Targets a Disease With No Approved Medicines - kalkine.ca
Amgen Inc Agencies, 2017 - OpenSecrets
Amgen (NASDAQ:AMGN) Reports Positive Dazodalibep Data in Sjogren's - kalkinemedia.com
Amgen stock draws attention after a Phase 3 trial win - AD HOC NEWS
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth? - Yahoo Finance
Amgen (AMGN), What Is Behind The Fresh Attention? - Yahoo Finance
Amgen Stock Forecast: Sjögren’s Trial Success Tests AMGN’s Pipeline Outlook - TradingKey
Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus - Yahoo Finance
Amgen Inc Agencies, 2004 - OpenSecrets
Amgen (AMGN) Stock Forecast and Price Target 2026 - MarketBeat
Why Amgen’s Pipeline Just Got More Interesting - Yahoo Finance
Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back - Yahoo Finance
Amgen Inc Bills, 2008 - OpenSecrets
Amgen Inc. (AMGN) Stock forecasts - uk.finance.yahoo.com
Amgen Inc Agencies, 2011 - OpenSecrets
AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’ - stocktwits.com
How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story - Simply Wall Street
Amgen’s Deerfield office campus sold to Mesirow for $151M in sale-leaseback deal - Yahoo Finance
Yaron Werber: Celldex's Urticaria Drug Won't Carry a Black Box; Amgen Maps a $25 Billion Sjogren's Market - finance.biggo.com
Amgen (AMGN) Rises Higher Than Market: Key Facts - Yahoo Finance
Obesity Drug Sector Evolves as Amgen (AMGN) Advances Pipeline Am - GuruFocus
Mesirow buys Amgen’s Deerfield campus in $151 million sale-leaseback - Crain's Chicago Business
Amgen stock last at USD 410.86, up 1.19 percent in New York trading - AD HOC NEWS
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Yahoo Finance
Amgen stock trades at USD 406.04 after pipeline win - AD HOC NEWS
Amgen Inc. $AMGN Stock Purchased by Envestnet Portfolio Solutions Inc. - MarketBeat
Amgen stock heads into the open after a 0.01 percent loss - ad-hoc-news.de
Amgen Inc. (AMGN34.SA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amgen Gains as Sjögren's Drug Clears Phase 3 - GuruFocus
Amgen (AMGN) Stock Could Be 40% Undervalued On Phase 3 Sjögren’s Data - simplywall.st
Amgen reports positive topline Phase 3 Sjögren’s results - European Pharmaceutical Review
Amgen stock heads into the open after a 4.34 percent gain - AD HOC NEWS
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail
Amgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease - Yahoo! Finance Canada
QRG Capital Management Inc. Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Envestnet Asset Management Inc. Acquires 326,260 Shares of Amgen Inc. $AMGN - MarketBeat
When Colorectal Cancer Strikes Early - Amgen
Amgen stock was last quoted after the close - AD HOC NEWS
Amgen price target raised by Jefferies to $410 after positive Sjögren's data - Yahoo Finance
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
2.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):